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Centuries ago, an obscure report on an
unusual skin cancer launched the
modern era of cancer research. Ever
since, skin research has made key
contributions to our understanding of
the biology and biochemistry of cancer
pathogenesis. In 1775, Percival Pott
published his essay entitled Chirurgical
observations Relative to the Cataract,
the Polypus of the Nose, the Cancer
of the Scrotum, [etc.] describing the
origin of the ‘‘soot-wart’’, a cancer of
the inferior surface of the scrotum
occurring with high frequency in
English chimney sweeps (Brown and
Thornton 1957). Pott attributed the
cause of this tumor to ‘‘the lodgement
of soot in the rugae of the scrotum’’,
thus providing in one description the
first recognition of environmental and
occupational cancer, the first identifi-
cation of a human carcinogen, the
first opportunity for cancer prevention,
and a protocol for surgical treatment.
Included in that 797 word essay was
a remarkably detailed description
of the course of the disease from a
local confined lesion to invasive
and then disseminated lethal cancer.
These insights were little noticed
for almost 150 years until (Yamagiwa
and Ichikawa, 1918) reported that the
chronic topical application of coal tar
on rabbit ears produced cutaneous
squamous cell carcinomas, the first
chemical carcinogenesis experiment.
By describing the evolution Figure 1
of individual lesions, Yamagiwa and
Ichikawa concluded that cancer deve-
loped through multiple phenotypic
stages and progressed even after the
carcinogen was removed. Over the
ensuing 20 years, many biologists and
chemists sought to identify the active
carcinogen in coal tar, culminating in
1932 with the report by a group led by
Ernest Kennaway that 3,4 benzpyrene
was the potent polycyclic aromatic
hydrocarbon in coal tar that produced
cancers when topically applied to
mouse skin. Incorporated into this
project was the isolation or synthesis
of multiple carcinogenic hydrocarbons,
all recognized by their action as
skin carcinogens (summarized in
Kennaway, 1955).
At the same time, the availability
of synthetic carcinogens and a reliable
squamous cancer model emboldened a
group of pathologists and biologists to
methodically explore the pathogenesis
of the neoplastic skin lesions. For the
next two decades, these investigators
discovered concepts regarding skin
cancer development that dominate
our current understanding of cancer
development in almost all epithelial
tissues. In particular, the work of Cecil
Mottram, Friedewald and Rous (Rous
later won the Nobel Prize for his work
on the viral etiology of skin cancer),
and Berenblum and Shubik led to the
following conclusions on the biology of
cancer: cancer occurs through multiple
stages with distinct operational mecha-
nisms and required sequence; cancer
is more frequent when proliferating
tissues are exposed to carcinogens;
the extent of exposure or potency of
the carcinogen determines the latent
period for tumor development; tumor
development does not require conti-
nuous exposure to carcinogenic agents
and the effect of a subtumorigenic
carcinogen exposure is permanent;
tumors will develop after a subtumori-
genic carcinogen exposure if the target
tissue is subjected to regenerative
hyperplasia as caused by repeated
wounding or application of an irritant
(Berenblum and Shubik, 1947, 1949;
Mottram, 1944a, b; Berenblum and
Haran, 1955; Berenblum, 1957;
Friedewald and Rous, 1944). It was
Friedewald and Rous who coined the
terms ‘‘initiation’’ and ‘‘promotion’’ to
distinguish the irreversible action of a
carcinogen and the non-carcinogenic
reversible activity of an irritant, still a
major part of the cancer lexicon today.
One of the important additions to the
skin cancer protocols provided by
Berenblum was the use of topical
croton oil, a non-carcinogenic skin
irritant that induced the outgrowth of
tumors from skin that had been treated
with a subtumorigenic dose of
carcinogen (initiated).
Croton oil (Crotonis Oleum) is pre-
pared from the seeds of Croton tiglium,
a tree belonging to the natural order
Euphorbiales and family Euphorbia-
ceae. Croton oil had been used for
centuries as folk medicine and was
known to induce inflammation and
peeling of skin when applied topically
and diarrhea when taken internally. Its
potency to promote tumors on skin
catalyzed interest among cancer biolo-
gists to identify the active compounds
contained within the complex mixture.
In a series of brilliant chemical puri-
fications and analyses, Van Duuren and
Hecker almost simultaneously identified
phorbol myristate acetate (12-O-tetra-
decanoyl-phorbol-13-acetate), commonly
E2 SEPTEMBER 2014 MILESTONES | CUTANEOUS BIOLOGY
known as PMA or TPA, as the most
potent skin tumor promoter in the oil
(Van Duuren and Orris, 1965; Hecker,
1968).Using the now pure tumor
promoter, a large cadre of scientists
embarked on studies to understand
its mechanism of action. To their
surprise, PMA/TPA had a myriad of
pleiotropic effects on cells and
tissues, including growth stimulation
or apoptosis, stimulation or inhibition
of differentiation, stimulated secretion
and migration, and many other cellular
changes depending on the cell type
and context under study. In skin
and keratinocytes, PMA/TPA had a
biphasic influence, stimulating imma-
ture basal cells to proliferate while
accelerating differentiation in commit-
ted cells. Remarkably, skin tumor cells
were much less responsive to TPA-
induced terminal differentiation than
normal keratinocytes (Yuspa et al.,
1982, 1986). The mystery surround-
ing these pleiotropic responses to
PMA/TPA became transparent when
Blumberg and colleagues discovered
specific cellular receptors for the tumor
promoting phorbol esters in brain and
skin (Delclos et al., 1980; Dunphy
et al., 1980). Shortly thereafter, the
group of Nishizuka identified PMA/TPA
as a potent ligand for binding and
activation of protein kinase C
(Castagna et al., 1982). The discovery
of PKC as the PMA/TPA receptor
launched a multitude of studies in the
ensuing 30 years, defining PKC as a
multi-isoform family of protein kinases.
Made possible by initial observations
on skin cancer, these subsequent
studies revealed intimate details of the
PKC signal transduction pathway and
its essentiality for many critical bio-
logical functions in cells and tissues
(Griner and Kazanietz, 2007). By its
dual function on skin keratinocytes to
induce differentiation or proliferation
in subpopulations of normal keratino-
cytes and its additional proinflam-
matory action, PMA/TPA provided the
necessary irritation and regenerative
hyperplasia to promote the outgrowth
of differentiation-resistant initiated
cells, as suggested 20 years earlier by
Berenblum, Mottram, and Rous.
The isolation and synthesis of 3,4
benzpyrene by Kennaway encouraged
multiple groups to investigate the
carcinogenicity of other polycyclic
hydrocarbons on mouse skin. Iball
(1939) compiled a list of comparative
potency of cyclic hydrocarbon mole-
cules for inducing skin tumors (Iball
Index). It made obvious that carcino-
gens were highly specific, with
stereoisomers often varying greatly in
potency. How they worked and their
target remained an open question. In
1964, Brooks and Lawley published
a landmark report addressing this
question (Brookes and Lawley, 1964).
Mouse skin painting of radiolabeled
agents selected from the Iball Index
resulted in covalent binding to DNA,
demonstrating a strong correlation of
carcinogenic potency with binding
to DNA but not RNA or protein.
Furthermore, kinetic studies showed
that carcinogen–DNA binding per-
sisted for extended periods, and peak
binding was delayed after application,
suggesting that metabolic activation
was required. These findings bolstered
the mutation theory of cancer patho-
genesis, and shortly after, Bates and
Yuspa showed that 7,12 dimethyl-
benza(a) anthracene, the most potent
carcinogen on the Iball Index, could
bind to the parental strand of replicat-
ing epidermal DNA and serve as a
template for daughter strands (Bates
et al., 1970), a requirement for fixing a
mutational event. In the decade of the
1970s, much effort was directed
toward understanding the metabolic
activation of carcinogens and how to
intervene in the process as a mecha-
nism of cancer prevention. With a
Occupational









































Figure 1. Milestones in cancer research. Shown is a timeline of important landmarks in cancer research first defined by studies of skin cancer pathogenesis or
experimental skin carcinogenesis. As shown in the more recent era, such discoveries continue to be made and now provide therapeutic breakthroughs as well as
insights into causation.
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focus on 3,4 benzpyrene, the Sims
laboratory discovered that the DNA-
binding product from topically treated
mouse skin was consistent with the 7,8-
dihydro-7,8-dihydroxybenzo(a) pyrene
9,10 oxide as the ultimate carcinogenic
species (Grover et al., 1976). This and
similar studies led to the elaboration
of the complete metabolic activation
pathway for benzpyrene and subse-
quently other polycyclic aromatic
hydrocarbon carcinogens (Levin et al.,
1982). The remarkable specificity of
the metabolic process was demon-
strated by the marked differences in
carcinogenic potency by optical enan-
tiomers of the 7,8-diol-9,10-epoxides
of 3,4 benzpyrene painted on mouse
skin (Slaga et al., 1979).
In 1981, the first indication of the
phenotype of initiated cells came with
the discovery that a small subpopula-
tion of keratinocytes isolated from
initiated mouse skin was resistant
to differentiation in culture induced
by elevating extracellular calcium, a
potent differentiation signal (Yuspa and
Morgan, 1981). The same phenotype
was later determined to characterize
keratinocytes treated with carcinogens
in vitro or isolated from papillomas
(Kilkenny et al., 1985; Yuspa et al.,
1986). Nevertheless, the molecular
change that determined this pheno-
typic divergence remained obscure.
With the identification of DNA as the
ultimate target for carcinogenesis and
the recognition of the remarkable
specificity of ultimate carcinogenic
species, attention turned to identifying
the genetic targets that converted
normal keratinocytes into initiated
cells. This was a particularly daunting
task in the late 1970s, as at that time
there were no databases that cataloged
the number and sequence of genes in
the genome, let alone how many were
potential targets for tumor initiation.
The number and locations of initiated
cells in the skin was also completely
obscure, making this particular
problem like finding a single needle
in a whole field of haystacks. As is
often the case in science, parallel
experiments in several laboratories
working neither on skin nor on
chemical carcinogenesis provided the
solution: it was possible to identify the
needle, in the form of DNA, by trans-
ferring it from tumor cells into (almost)
normal cells, and selecting for those
that became transformed. These
experiments, carried out in the late
70s and early 80s, had an electrifying
effect on the whole community of
cancer researchers. The groups of
Weinberg, Wigler, and others demon-
strated in a technical tour de force that
it was possible to transfer naked DNA
from human tumor cells into mouse
(NIH/3T3) fibroblasts, endowing them
with transformed properties (Shih et al.,
1979; Shilo and Weinberg, 1981;
Perucho et al., 1981). While the exist-
ence of cellular ‘‘proto-oncogenes’’,
akin to those found in transforming
retroviruses, had been shown to exist in
the human and mouse genomes in the
Nobel Prize-winning work of Varmus
and Bishop, this work showed for the
first time that DNA, and DNA alone,
was capable of causing cancerous
changes in the absence of exogenous
carcinogens or other agents. These
seminal experiments also demon-
strated for the first time that there was
a qualitative change in DNA from
tumors, as the same experiment
transferring the same amounts of DNA
from normal tissues did not cause
transformation.
The culprits ultimately identified in
these experiments turned out to be
individual members of the Ras gene
family (HRAS, KRAS, and NRAS),
which had been previously known to
be hijacked by a series of transforming
retroviruses (Parada et al., 1982; Santos
et al., 1982; Taparowsky et al., 1982).
A crucial difference between the trans-
forming versions of these human genes
and their normal cellular counterparts
was the acquisition of specific point
mutations leading to constitutive
activation and independence from
normal growth control signals. These
provocative observations raised the
possibility that chemical carcinogens,
known to cause single point mutations
in DNA, could in fact cause the first
initiating step in carcinogenesis by
mutating and consequently activating
one of these Ras genes. The mouse skin
model of two-stage carcinogenesis
provided an ideal vehicle to address
these questions. In a series of trans-
fection experiments using DNA
isolated from mouse skin tumors and
corresponding cell lines (Balmain and
Pragnell, 1983), a single member of the
Ras gene family, Hras, was identified as
the transforming agent. This constant
activation of only one family member
was in contrast to the emerging data on
human transforming genes at the time,
which suggested that all RAS gene
family members could be activated in
different tumor types, with KRAS being
the most commonly mutated target
gene. Much later, it transpired that the
mouse data did in fact presage what
would be found in human cancers,
where it has been shown that although
HRAS is less frequently activated gene-
rally in human cancers than KRAS, it
appears to have a specific role in
transformation of human squamous
epithelial cells of the skin, lung, head
and neck, and bladder (Agrawal et al.,
2011; Wang et al., 2011; The Cancer
Genome Atlas Research Network,
2012).
It seemed then that the elusive
initiating event for mouse skin carcino-
genesis had been identified, but several
additional studies were required to
fulfill Koch’s postulates and demon-
strate causality. First, if this was the
initial event in skin cancer develop-
ment, it should be detectable in the
earliest forms of skin cancer induced in
the mouse model – benign papillomas.
This turned out in fact to be the case
(Balmain et al., 1984), and furthermore
it was demonstrated that Ras mutations
have additional roles beyond initiation,
as gene copy number increases are
seen during progression to malignancy
(Quintanilla et al., 1986). Second, if the
initiating carcinogen causes the Hras
mutation, by extension of the argu-
ments presented above regarding the
specific nature of the interaction bet-
ween carcinogens and DNA, it would
be postulated that any mutations detec-
ted would be specific for the particular
carcinogen used. The possibility that
this correlation applies to Ras gene
mutations was first suggested from a
study of carcinogen-induced rat mam-
mary tumors (Sukumar et al., 1983).
Mammary carcinomas induced by
treatment with the carcinogen MNU
(N-Nitroso N-Methyl Urea) were
E4 SEPTEMBER 2014 MILESTONES | CUTANEOUS BIOLOGY
shown to contain activating G–A tran-
sition mutations at codon 12 of Hras,
but similar tumors induced by treat-
ment with 7,12-dimethylbenz[a]an-
thracene (DMBA) did not harbor this
mutation, suggesting that the mecha-
nisms by which the mutations arose
were carcinogen specific. Studies of
skin carcinogenesis identified the nat-
ure of mutations induced by DMBA
(Bizub et al., 1986; Quintanilla et al.,
1986) and demonstrated that within the
same skin model system, the mutations
found in Hras were indeed specific for
the initiating carcinogen (Brown et al.,
1990). Tumors initiated by exposure to
methylating agents MNU and MNNG
harbored codon 12G–A transitions,
whereas those initiated by DMBA
contained almost exclusively A–T
transversions at Hras codon 61. The
latter observation was compatible with
studies showing that DMBA, in contrast
to alternative polycyclic hydrocarbons
such as Benzo(a) pyrene, was capable
of extensive adduct formation with
adenosine residues in DNA (Dipple,
et al., 1983). These data, together
with evidence showing that isolated
DNA clones encoding normal HRAS
acquired transforming properties after
incubation with a reactive ‘‘ultimate
carcinogen’’ derived from Benzo(a)
pyrene (Marshall et al., 1984), helped
to establish the chain of events linking
the chemical nature of the initiating
carcinogen to the mechanisms by
which normal RAS proto-oncogenes
become activated to transforming
alleles.
There remained, however, the issue
of biological causality. While Hras
mutations could be detected in early
skin lesions, and the mutations were
compatible with their being induced
specifically at the time of initiation,
were these mutant genes in fact cap-
able of initiating tumorigenesis in
keratinocytes as opposed to fibroblasts
cultures, and in vivo rather than in cell
culture systems? These questions were
comprehensively addressed by demon-
strating that (a) keratinocytes infected
in vitro with viruses encoding trans-
forming Hras genes could generate
benign papillomas on grafting on to
nude mouse skin (Roop et al., 1986)
and (b) direct infection of mouse skin
keratinocytes in vivo with a retro-
virus capable of expressing mutant
Ras replicated all of the features of
chemical carcinogenesis, including
permanence of the initiated state,
dependence on treatment with tumor
promoters, and progression of benign
tumors to malignant carcinomas
(Brown et al., 1986).
These data established the molecular
nature of the initiating event in skin
carcinogenesis, but several major ques-
tions remained to be resolved: what
and where is the cell of origin of skin
tumors, and do all initiated cells, or all
papillomas, have the same capacity for
malignant progression? Hennings and
Yuspa found evidence for heterogene-
ity in the propensity for papillomas to
progress to malignancy. Papillomas
that developed soon after beginning
promotion treatment appeared to pro-
gress to carcinomas at a high frequency
(Hennings et al., 1985). However, it
was not clear whether these ‘‘high-
risk’’ papillomas had arisen from a
specific subpopulation of initiated
(stem?) cells, or because of stochastic
acquisition of a secondary genetic
change after initiation. Evidence in
favor of the former scenario came
from experiments involving physical
removal of cells in the interfollicular
epidermis by abrasion after DMBA
initiation (Morris et al., 2000). This
procedure led to a 50% decrease in the
number of benign papillomas, but the
total number of malignant carcinomas
remained the same, suggesting that
cells capable of conversion to malig-
nancy may reside preferentially in the
hair follicle region that was spared by
the abrasion process. The advent of
transgenic mouse technology, with the
capacity to direct expression of mutant
Ras and other genes to specific target
cells within the skin, allowed further
refinement of the concepts of initiation
and progression in the skin model.
When promoters of genes expressed
in interfollicular suprabasal differenti-
ating cells (Keratin 10 and Keratin 1)
were used to express mutant Hras
in vivo, this led to the development of
benign papillomas that were extremely
sensitive to promotion by wounding
or TPA treatment, but failed to progress
to malignancy (Bailleul et al., 1990;
Greenhalgh et al., 1993). However, the
use of a modified Keratin 5 promoter to
target the same mutant Hras to basal
cells within the hair follicle, including
the bulge region containing the puta-
tive stem cells (Cotsarelis et al., 1990),
led to the development of promoter-
independent lesions that progressed to
carcinomas (Brown et al., 1998). While
a range of stem and progenitor cells
may be capable of generating papillo-
mas, only a select subset of target cells,
possibly within the hair follicle stem
cell compartment, may be capable of
generating high-risk papillomas that
undergo malignant conversion at high
frequency.
Further evidence for heterogeneity in
the papilloma population came from
genetic mapping studies using crosses
between skin tumor susceptible and
resistant mice. This analysis identified
some loci harboring polymorphisms
that influenced susceptibility to devel-
opment of carcinomas, but the same
loci did not obviously affect papilloma
numbers (Nagase et al., 1995;
Wakabayashi et al., 2007), suggesting
that early and late stages are under
separate genetic control. All of these
experiments, taken together, indicate
that while malignant tumors obviously
develop from premalignant lesions, this
is not simply a stochastic process of
progression, and subsets of papillomas
have a particularly high propensity to
become carcinomas. Loss of the p53
tumor suppressor gene does not appear
to increase the number of initiated cells
or benign papillomas, but specifically
has an important role in promoting
malignant progression (Kemp et al.,
1993). Clarification of the genetic and
biological basis for these observations
may have profound implications for
our understanding of premalignancy,
and consequently for the development
of strategies for recognition of high-risk
lesions in human populations. Of
course the story does not stop here.
Studying cancer pathogenesis in skin
continues to yield important insights
into the pathogenesis of cancer in other
lining epithelia of internal organs both
at the molecular level and regarding
the required interactions among tissue
compartments, signaling pathways,
and organismal responses. These are
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the major lethal cancers of humans to
which skin research has made enor-
mous contributions.
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